Analysts Set Inovio Pharmaceuticals Inc (NASDAQ:INO) PT at $6.69

Share on StockTwits

Inovio Pharmaceuticals Inc (NASDAQ:INO) has earned an average recommendation of “Buy” from the eight research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $6.69.

INO has been the subject of several analyst reports. Maxim Group reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Inovio Pharmaceuticals in a report on Sunday, August 11th. HC Wainwright set a $13.00 price objective on Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, September 18th. Citigroup reaffirmed a “buy” rating and issued a $4.00 price objective (down from $7.00) on shares of Inovio Pharmaceuticals in a report on Monday, September 16th. ValuEngine raised Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Piper Jaffray Companies dropped their price objective on Inovio Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a report on Wednesday, July 17th.

In other news, Director David B. Weiner sold 16,352 shares of the business’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $2.72, for a total transaction of $44,477.44. Following the completion of the transaction, the director now owns 797,110 shares of the company’s stock, valued at approximately $2,168,139.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 7.90% of the stock is currently owned by insiders.

Several institutional investors have recently bought and sold shares of the company. Wedbush Securities Inc. acquired a new position in shares of Inovio Pharmaceuticals during the 3rd quarter worth $34,000. Jane Street Group LLC acquired a new position in Inovio Pharmaceuticals in the 2nd quarter worth about $275,000. Cubist Systematic Strategies LLC increased its holdings in Inovio Pharmaceuticals by 140.2% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 32,802 shares of the biopharmaceutical company’s stock worth $96,000 after purchasing an additional 19,144 shares in the last quarter. Vanguard Group Inc. increased its holdings in Inovio Pharmaceuticals by 0.7% in the 2nd quarter. Vanguard Group Inc. now owns 4,860,200 shares of the biopharmaceutical company’s stock worth $14,289,000 after purchasing an additional 35,018 shares in the last quarter. Finally, A.R.T. Advisors LLC increased its holdings in Inovio Pharmaceuticals by 82.1% in the 2nd quarter. A.R.T. Advisors LLC now owns 51,874 shares of the biopharmaceutical company’s stock worth $153,000 after purchasing an additional 23,389 shares in the last quarter. 46.18% of the stock is owned by institutional investors.

INO traded down $0.12 during trading on Friday, hitting $2.24. The stock had a trading volume of 42,917 shares, compared to its average volume of 496,539. The company has a 50 day moving average price of $2.24 and a 200-day moving average price of $2.86. The firm has a market cap of $221.82 million, a price-to-earnings ratio of -2.16 and a beta of 2.07. Inovio Pharmaceuticals has a one year low of $1.91 and a one year high of $5.68. The company has a debt-to-equity ratio of 1.49, a current ratio of 4.59 and a quick ratio of 4.59.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.02). The company had revenue of $0.14 million during the quarter, compared to analyst estimates of $4.69 million. Inovio Pharmaceuticals had a negative net margin of 1,560.70% and a negative return on equity of 142.10%. During the same period in the prior year, the firm earned ($0.07) earnings per share. As a group, sell-side analysts predict that Inovio Pharmaceuticals will post -1.06 EPS for the current fiscal year.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

Read More: How are the companies in the S&P 500 selected?

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Mason Street Advisors LLC Lowers Stock Holdings in Merck & Co., Inc.
Mason Street Advisors LLC Lowers Stock Holdings in Merck & Co., Inc.
Mason Street Advisors LLC Buys 93 Shares of Facebook, Inc.
Mason Street Advisors LLC Buys 93 Shares of Facebook, Inc.
Rossmore Private Capital Sells 1,000 Shares of CDK Global Inc
Rossmore Private Capital Sells 1,000 Shares of CDK Global Inc
Rossmore Private Capital Purchases 80 Shares of SPDR S&P 500 ETF Trust
Rossmore Private Capital Purchases 80 Shares of SPDR S&P 500 ETF Trust
Rossmore Private Capital Reduces Position in Visa Inc
Rossmore Private Capital Reduces Position in Visa Inc
Cognizant Technology Solutions Corp  Shares Sold by Penobscot Investment Management Company Inc.
Cognizant Technology Solutions Corp Shares Sold by Penobscot Investment Management Company Inc.


© 2006-2019 Ticker Report